Published in Immunotherapy Weekly, May 18th, 2005
These patients were treated in a phase II clinical study with the investigational fully human antiCTLA-4 antibody, MDX-010, in combination with MDX-1379, a gp100 melanoma vaccine. The phase II clinical trial was conducted by Steven A. Rosenberg, MD, PhD, chief of surgery at the U.S. National Cancer Institute, under a Cooperative Research and Development Agreement with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.